EMA Application withdrawn: Luveniq (voclosporin) — Lux Biosciences GmbH

View source ↗

Summary

The EMA withdrew the Luveniq (voclosporin) application from Lux Biosciences GmbH for the therapeutic area of uveitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveitis

Drugs mentioned

• Luveniq (voclosporin)

Snippet

Status: Application withdrawn. Therapeutic area: Uveitis. MAH: Lux Biosciences GmbH. Decision date: 24/06/2011